References
- van LeeuwaardeRS, AhmadS, LinksTP, GilesRH. Von Hippel–Lindau syndrome. In: GeneReviews®.AdamMP, ArdingerHH, PagonRA ( Eds). University of Washington, WA, USA (1993).
- LonserRR, ButmanJA, HuntoonKet al.Prospective natural history study of central nervous system hemangioblastomas in von Hippel–Lindau disease. J. Neurosurg.120(5), 1055–1062 (2014).
- HuntoonK, ShepardMJ, LukasRV, McCutcheonIE, DanielsAB, AsthagiriAR. Hemangioblastoma diagnosis and surveillance in von Hippel–Lindau disease: a consensus statement. J. Neurosurg.136(6), 1–6 (2021).
- KibelA, IliopoulosO, DeCaprioJA, KaelinWG. Binding of the von Hippel–Lindau tumor suppressor protein to Elongin B and C. Science269(5229), 1444–1446 (1995).
- MaxwellPH, WiesenerMS, ChangGWet al.The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature399(6733), 271–275 (1999).
- GossageL, EisenT, MaherER. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer15(1), 55–64 (2015).
- LinQ, CongX, YunZ. Differential hypoxic regulation of hypoxia-inducible factors 1α and 2α. Mol. Cancer Res.9(6), 757–765 (2011).
- CourtneyKD, MaY, Diazde Leon Aet al.HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin. Cancer Res.26(4), 793–803 (2020).
- DeeksED. Belzutifan: first approval. Drugs81(16), 1921–1927 (2021).
- JonaschE, DonskovF, IliopoulosOet al.Belzutifan for renal cell carcinoma in von Hippel–Lindau disease. N. Engl. J. Med.385(22), 2036–2046 (2021).